Business Wire

JELLYFISH

23.2.2021 15:02:15 CET | Business Wire | Press release

Share
Jellyfish Acquires 5 Companies, Fueling Global Expansion With New Digital Capabilities

Jellyfish , the digital marketing partner to the world's leading brands (i.e., Samsung, Uber, Nestle, Deckers, Spotify, and eBay), announced today the acquisition of 5 companies—each a known leader in the digital space. Jellyfish’s rapid expansion comes against a backdrop of consolidation and challenges in the traditional agency sector as the company’s capabilities lie in helping brands during their digital transformation journey. Jellyfish’s expansion follows previous acquisitions with a significant investment from Fimalac Group in 2019. The company represents a new kind of digital business, where agency services are combined with consultancy, training, and cutting-edge technologies to deliver the best possible outcomes for clients. Launched in 2005, it has also become one of a select few globally managed Google Marketing Platform Partners, growing at an average of 45% per annum consistently over the last eight years.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005716/en/

Current eMarketer forecasts indicate that total media ad spend is expected to hit more than 600 billion in 2021 thus, to remain competitive, and to increase media effectiveness, companies must cut through a saturated digital landscape and provide seamless, relevant communications across all channels and touchpoints. The acceleration of digital transformation in response to the global pandemic has created a greater need for brands to partner with companies that can help them navigate and meet the challenges of driving growth and sustainability.

“Our mission is to ensure that our clients have all the resources needed to fully embrace digital transformation and reach results that transcend every expectation. Coming off a year of unprecedented disruption and transformation in digital marketing, Jellyfish continues to grow worldwide, entering new markets of Australia and Mexico and increasing our presence in France, Brazil, and the US—adding new capability and talent around the globe, with a focus on content creation and localization, e-commerce, creative, and data optimization,” says Rob Pierre CEO of Jellyfish. “These acquisitions are key in driving prominence and growth in the marketplace and we believe nothing is impossible or beyond the reach of our clients,” Pierre adds.

“These acquisitions bring powerful enhancements to our portfolio of services by expanding our depth of expertise, geographical reach, and our offerings across several continents and regions,” says Chris Lee, COO, Jellyfish.

Expanded expertise, technologies:

Seelk
Software and consultancy for Amazon Marketplace
Splash
Creative technology and services with global localization
Quill
Global Performance Content for e-commerce
Webedia Brand Services
Gamification, content, data, technology services and enterprise data strategies

Expanded global footprint:

Data Runs Deep - Australia
Consulting, implementation, and training for data solutions

For additional information on each Jellyfish acquisition company, click here .

Other recent acquisitions that expanded our global footprint:

Reamp - Brazil
Programmatic marketing, marketing automation, and digital campaign performance (acquired in H2 2020)
San Pancho - Mexico & Colombia
Full-funnel digital marketing capabilities and analytics expertise (acquired in H2 2020)

About Jellyfish

Jellyfish, part of the Fimalac Group, is a global partner in digital marketing and transformation to some of the world's leading brands including Samsung, Uber, Nestle, Orange, Spotify & eBay. Jellyfish represents a new kind of digital business, where agency services are combined with consultancy, training, and cutting-edge technologies to deliver the best possible outcomes for clients. Employing over 2000 people across 40 offices globally, and with further expansion on the horizon, Jellyfish aims to be the first-choice global partner for any brand’s digital requirements. Launched in 2005, Jellyfish has also grown to become one of a select few globally managed Google Marketing Partners. Growing at an average of 45% per annum consistently over the last eight years, Jellyfish is proud to be at the forefront of the global digital economy.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye